vs
EXACT SCIENCES CORP（EXAS）与ROKU, INC（ROKU）财务数据对比。点击上方公司名可切换其他公司
ROKU, INC的季度营收约是EXACT SCIENCES CORP的1.6倍（$1.4B vs $878.4M），ROKU, INC净利率更高（5.8% vs -9.8%，领先15.6%），EXACT SCIENCES CORP同比增速更快（23.1% vs 16.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $106.6M），过去两年ROKU, INC的营收复合增速更高（25.8% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Roku是美国流媒体技术企业，2002年由安东尼·伍德创立，主营数字媒体播放器、电视硬件生产，流媒体内容分发及平台广告运营。截至2024年覆盖用户达1.45亿，是美国流媒体视频分发领域的市场领导者，业务覆盖澳、加、法、德、英及拉美多国。
EXAS vs ROKU — 直观对比
营收规模更大
ROKU
是对方的1.6倍
$878.4M
营收增速更快
EXAS
高出7.0%
16.1%
净利率更高
ROKU
高出15.6%
-9.8%
自由现金流更多
EXAS
多$13.9M
$106.6M
两年增速更快
ROKU
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.4B |
| 净利润 | $-86.0M | $80.5M |
| 毛利率 | 70.1% | 43.5% |
| 营业利润率 | -9.4% | 4.7% |
| 净利率 | -9.8% | 5.8% |
| 营收同比 | 23.1% | 16.1% |
| 净利润同比 | 90.1% | 326.4% |
| 每股收益（稀释后） | $-0.45 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASROKU
| Q4 25 | $878.4M | $1.4B | ||
| Q3 25 | $850.7M | $1.2B | ||
| Q2 25 | $811.1M | $1.1B | ||
| Q1 25 | $706.8M | $1.0B | ||
| Q4 24 | $713.4M | $1.2B | ||
| Q3 24 | $708.7M | $1.1B | ||
| Q2 24 | $699.3M | $968.2M | ||
| Q1 24 | $637.5M | $881.5M |
净利润EXASROKU
| Q4 25 | $-86.0M | $80.5M | ||
| Q3 25 | $-19.6M | $24.8M | ||
| Q2 25 | $-1.2M | $10.5M | ||
| Q1 25 | $-101.2M | $-27.4M | ||
| Q4 24 | $-864.6M | $-35.5M | ||
| Q3 24 | $-38.2M | $-9.0M | ||
| Q2 24 | $-15.8M | $-34.0M | ||
| Q1 24 | $-110.2M | $-50.9M |
毛利率EXASROKU
| Q4 25 | 70.1% | 43.5% | ||
| Q3 25 | 68.6% | 43.4% | ||
| Q2 25 | 69.3% | 44.8% | ||
| Q1 25 | 70.8% | 43.6% | ||
| Q4 24 | 69.0% | 42.7% | ||
| Q3 24 | 69.4% | 45.2% | ||
| Q2 24 | 69.8% | 43.9% | ||
| Q1 24 | 70.0% | 44.1% |
营业利润率EXASROKU
| Q4 25 | -9.4% | 4.7% | ||
| Q3 25 | -3.0% | 0.8% | ||
| Q2 25 | -0.3% | -2.1% | ||
| Q1 25 | -13.6% | -5.7% | ||
| Q4 24 | -122.8% | -3.3% | ||
| Q3 24 | -5.6% | -3.4% | ||
| Q2 24 | -3.8% | -7.4% | ||
| Q1 24 | -16.7% | -8.2% |
净利率EXASROKU
| Q4 25 | -9.8% | 5.8% | ||
| Q3 25 | -2.3% | 2.0% | ||
| Q2 25 | -0.1% | 0.9% | ||
| Q1 25 | -14.3% | -2.7% | ||
| Q4 24 | -121.2% | -3.0% | ||
| Q3 24 | -5.4% | -0.9% | ||
| Q2 24 | -2.3% | -3.5% | ||
| Q1 24 | -17.3% | -5.8% |
每股收益（稀释后）EXASROKU
| Q4 25 | $-0.45 | $0.55 | ||
| Q3 25 | $-0.10 | $0.16 | ||
| Q2 25 | $-0.01 | $0.07 | ||
| Q1 25 | $-0.54 | $-0.19 | ||
| Q4 24 | $-4.69 | $-0.24 | ||
| Q3 24 | $-0.21 | $-0.06 | ||
| Q2 24 | $-0.09 | $-0.24 | ||
| Q1 24 | $-0.60 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $2.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.7B |
| 总资产 | $5.9B | $4.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASROKU
| Q4 25 | $964.7M | $2.3B | ||
| Q3 25 | $1.0B | $2.3B | ||
| Q2 25 | $858.4M | $2.3B | ||
| Q1 25 | $786.2M | $2.3B | ||
| Q4 24 | $1.0B | $2.2B | ||
| Q3 24 | $1.0B | $2.1B | ||
| Q2 24 | $946.8M | $2.1B | ||
| Q1 24 | $652.1M | $2.1B |
股东权益EXASROKU
| Q4 25 | $2.4B | $2.7B | ||
| Q3 25 | $2.5B | $2.6B | ||
| Q2 25 | $2.5B | $2.6B | ||
| Q1 25 | $2.4B | $2.5B | ||
| Q4 24 | $2.4B | $2.5B | ||
| Q3 24 | $3.2B | $2.5B | ||
| Q2 24 | $3.2B | $2.4B | ||
| Q1 24 | $3.1B | $2.4B |
总资产EXASROKU
| Q4 25 | $5.9B | $4.4B | ||
| Q3 25 | $5.9B | $4.4B | ||
| Q2 25 | $5.8B | $4.3B | ||
| Q1 25 | $5.7B | $4.2B | ||
| Q4 24 | $5.9B | $4.3B | ||
| Q3 24 | $6.7B | $4.3B | ||
| Q2 24 | $6.7B | $4.1B | ||
| Q1 24 | $6.4B | $4.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $107.7M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $106.6M |
| 自由现金流率自由现金流/营收 | 13.7% | 7.6% |
| 资本支出强度资本支出/营收 | 3.6% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 1.34× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $478.4M |
8季度趋势，按日历期对齐
经营现金流EXASROKU
| Q4 25 | $151.7M | $107.7M | ||
| Q3 25 | $219.9M | $127.6M | ||
| Q2 25 | $89.0M | $109.7M | ||
| Q1 25 | $30.8M | $138.7M | ||
| Q4 24 | $47.1M | $79.3M | ||
| Q3 24 | $138.7M | $68.7M | ||
| Q2 24 | $107.1M | $23.4M | ||
| Q1 24 | $-82.3M | $46.7M |
自由现金流EXASROKU
| Q4 25 | $120.4M | $106.6M | ||
| Q3 25 | $190.0M | $126.5M | ||
| Q2 25 | $46.7M | $108.6M | ||
| Q1 25 | $-365.0K | $136.8M | ||
| Q4 24 | $10.7M | $76.8M | ||
| Q3 24 | $112.6M | $67.6M | ||
| Q2 24 | $71.2M | $22.5M | ||
| Q1 24 | $-120.0M | $46.0M |
自由现金流率EXASROKU
| Q4 25 | 13.7% | 7.6% | ||
| Q3 25 | 22.3% | 10.4% | ||
| Q2 25 | 5.8% | 9.8% | ||
| Q1 25 | -0.1% | 13.4% | ||
| Q4 24 | 1.5% | 6.4% | ||
| Q3 24 | 15.9% | 6.4% | ||
| Q2 24 | 10.2% | 2.3% | ||
| Q1 24 | -18.8% | 5.2% |
资本支出强度EXASROKU
| Q4 25 | 3.6% | 0.1% | ||
| Q3 25 | 3.5% | 0.1% | ||
| Q2 25 | 5.2% | 0.1% | ||
| Q1 25 | 4.4% | 0.2% | ||
| Q4 24 | 5.1% | 0.2% | ||
| Q3 24 | 3.7% | 0.1% | ||
| Q2 24 | 5.1% | 0.1% | ||
| Q1 24 | 5.9% | 0.1% |
现金转化率EXASROKU
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 5.14× | ||
| Q2 25 | — | 10.45× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
ROKU
| Services | $1.2B | 88% |
| Products | $170.9M | 12% |
